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ABSTRACT
Introduction Pancreatic neuroendocrine tumors are slow-growing tumors that account for 1-2% of all pancreatic malignancies. Enucleation 
of low-grade pancreatic neuroendocrine tumors has the advantage of avoiding short and long-term morbidities related to formal resections; 
however, it carries a risk of significant post-operative pancreatic fistula, especially if the tumor is close to the main pancreatic duct. We have 
recently started using intra-operative ERCP to facilitate enucleation of pNETs ≤ 3 mm from MPD. This technique has not previously been 
described in the literature. Methods Intraoperative ERCP is considered for patients with pNETs ≤ 3 mm from main pancreatic duct who are 
being considered for enucleation. Intraoperative pancreatography is performed after enucleation, to assess for extravasation of contrast 
from main pancreatic duct or major side branches at the site of tumor excision. If no extravasation is noted, a pancreatic stent is deployed, 
and the procedure is terminated. Significant contrast extravasation on pancreatogram is considered an indicator for the development 
of significant post-operative pancreatic fistula, and the procedure needs to be converted to a formal pancreatic resection. Results We 
described the steps of the technique, accompanied by images from a patient case. A treatment algorithm is provided detailing a step-by-
step approach in patients considered for ERCP assisted enucleation. Conclusion The described technique of ERCP assisted enucleation 
allows safe resection of pancreatic neuroendocrine tumors ≤ 3 mm from main pancreatic duct through assessment of main pancreatic duct 
integrity, decreasing the risk of significant post-operative pancreatic fistula, and avoiding the morbidity of major pancreatic resections.
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INTRODUCTION
Pancreatic Neuroendocrine Tumors (pNETs) 
are rare, and account for 1-2% of all pancreatic 
malignancies. PNETs are usually indolent but can often 
have unpredictable biologic behavior with potential for 
malignant transformation. Additionally, pNETs can often 
be associated with inherited syndromes such as Multiple 
Endocrine Neoplasia type 1 (MEN-1) and Von Hippel-
Lindau disease (VHL), which can present at a younger 
age with multi-centric pancreatic lesions, adding further 
complexity to treatment decision making[1, 2, 3].
Surgical resection of pNETs remains the only curative 
treatment option and is regarded as the standard of 
care even in some cases with advanced disease. Surgical 
options include enucleation or standard pancreatic 
resections, such as Pancreaticoduodenectomy (PD), 
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parenchyma or if there is a concern for the integrity of 
MPD at conclusion of tumor enucleation.
RESULTS
Figure 1 shows a Magnetic Resonance Imaging (MRI) 
of a 17-year-old girl with MEN-I syndrome who was found 
to have a 1.7 cm insulinoma in the head of the pancreas 
after a work up for recurrent symptomatic hypoglycemia. 
She was managed using EAE technique described 
above. Figure 2 shows the appearance of the tumor on 
Endoscopic Ultrasound (EUS). The MPD cannot be seen 
in this image but was measured to be approximately 2 
mm from the deep tumor surface. The tumor was deep 
in the parenchyma and was enucleated successfully after 
identification with intraoperative ultrasound (Figure 3). 
ERCP obtained in the operating room showed an intact MPD 
without any significant extravasation at the enucleation 
site. Pancreatic stent was deployed due to depth of tumor, 
and the very close proximity to MPD. A surgical drain was 
left in the vicinity of enucleation site. The patient had an 
uneventful post-operative recovery without development 
of pancreatitis or significant POPF. She has continued to do 
well until the most recent follow-up.
Central Pancreatectomy (CP) or Distal Pancreatectomy 
(DP). Enucleation has the advantage of parenchymal 
preservation with minimal chance of endocrine or 
exocrine pancreatic insufficiency - features that make it 
an attractive option for younger patients with indolent 
pNETs, in whom one might want to avoid both short and 
long-term morbidity of a major pancreatic resection. 
However, any benefit that can be gained from enucleation 
must be weighed against the risk of Post-Operative 
Pancreatic Fistula (POPF), especially for tumors close to 
the Main Pancreatic Duct (MPD) (≤ 3 mm distance), due 
to increased risk of inadvertent injury to MPD or major 
side branch [1, 2, 3, 4, 5, 6, 7]. In fact, many surgeons now 
consider enucleation a relative contraindication for pNETs 
close to the MPD, choosing instead to proceed with more 
standard resections such as PD, CP or DP [1, 3, 4, 5, 6, 7]. 
In this paper we describe our approach of ERCP Assisted 
Enucleation (EAE) for deep pNETs (≤ 3 mm from the MPD) as 
a technique to increase safety of the procedure, by assessing 
for integrity of MPD and early identification of patients at 
high risk for development of POPF after enucleation [5, 6, 7].
METHODS AND TECHNIQUE
Patient Selection
Our technique of EAE is reserved for patients with 
pNETs that are ≤ 3 mm from MPD and who are otherwise 
candidates for enucleation based on tumor size and type. 
Operative Technique
The surgery can be performed as an open surgery or 
laparoscopically, depending on the location of tumor, 
patient characteristics and the experience of the surgeon. 
After general exploration, lesser sac is entered, and 
pancreas exposed. Intra-operative ultrasound is utilized 
to assess the pancreas, identify the tumor and re-measure 
distance of the pNET from the MPD. The tumor is then 
enucleated using standard surgical techniques. Care 
should be taken on deeper dissection to stay close to the 
tumor in order to avoid inadvertent injury to the MPD. 
After enucleation, the pancreatic parenchyma is carefully 
inspected. In absence of any obvious injury to the MPD, 
an on-table ERCP is performed. On ERCP images, careful 
attention should be given to any evidence of contrast 
extravasation from MPD or major side branch in the area 
of enucleation. If no leakage is apparent, a surgical drain 
is left in the vicinity of surgery, and the procedure is 
terminated. A PD stent should be placed to reduce the risk 
of post-ERCP pancreatitis, and for the treatment of small 
leaks, particularly following enucleation of deeper tumors, 
which may not be readily apparent on intraoperative 
pancreatogram. If the pancreatogram indicates significant 
contrast extravasation from the MPD or major side branch 
at the time of pancreatogram, this is taken as an indicator 
for the development of significant POPF, and the surgery 
is converted to a standard pancreatic resection (PD, CP 
or DP) depending on the location of pNET. Intraoperative 
ERCP can also be considered for enucleation of pNETs>3 
mm from the MPD if they are located deep in the pancreatic 
Figure 1. MRI showing a 1.7 cm pNET (insulinoma) in head of the 
pancreas (red circle) in a 17-year-old girl with MEN-I syndrome and 
recurrent symptomatic hypoglycemia.
Figure 2. EUS confirming a 1.7 cm pNET in the head of pancreas (red 
circle), approximately 2 mm from the MPD (not seen in this image). 
15JOP. Journal of the Pancreas - http://pancreas.imedpub.com/ - Vol. 21 No. 1 – Nov 2020. [ISSN 1590-8577]
JOP. J Pancreas (Online) 2020 Feb 28; 21(1):13-16.
DISCUSSION
PNETs are rare, usually well differentiated, and if 
malignant, carry a better prognosis than pancreatic 
adenocarcinoma [1]. These tumors are usually sporadic; 
however about 10-15% are associated with inherited 
genetic disorders such as MEN-1 and VHL [2, 3]. 
Surgery is the mainstay of treatment of patients with 
pNETs, and is indicated to achieve cure, control hormone 
hypersecretion, alleviate tumor related local compressive 
symptoms, and for palliation purposes in patients 
with advanced disease [2, 3]. Surgical options include 
enucleation of the tumor with parenchymal preservation, 
or standard pancreatic resections (PD, CP or DP) [1, 
4, 5]. pNETs<2 cm in size have a very low incidence of 
malignancy (6%) which makes enucleation an extremely 
attractive option for symptomatic and/or functional 
pNETS<2 cm [2]. Enucleation has the advantage of being 
less invasive than standard resections with a low (2-5%) 
risk of endocrine or exocrine insufficiency compared to 
a much higher risk of pancreatic insufficiency seen after 
PD, CP or DP, which approaches 50% in some studies [3, 
4, 5, 6, 8, 9]. Additionally, pancreatic enucleation results 
in less intraoperative blood loss, decreased length of 
surgery, and shorter hospital stay when compared 
to standard resections [5]. However, enucleation can 
lead to disruption of the main pancreatic duct or major 
branches manifesting as post-operative pancreatic fistula 
(POPF), which can significantly contribute to procedural 
morbidity. POPF rates after enucleation vary from 20-67% 
and can also range in severity from clinically insignificant 
(International Study Group for Pancreatic Fistula [ISGPF] 
grade A) to clinically significant (ISGPF grades B & C) [2, 
6, 7, 10], which might require additional procedures and 
prolonged hospitalization. Many studies have extensively 
looked at the risk of POPF after enucleation and have 
identified tumor size>3 cm, and distance of ≤ 3 mm from 
the pancreatic duct as risk factors for clinically significant 
POPF[2, 6, 7, 9]. Some studies have also shown a higher 
incidence of POPF after enucleation in patients with 
hereditary syndromes, especially MEN-1. Consequently, 
many surgeons now consider pNETs ≤ 3 mm from MPD as 
a contraindication to enucleation. Preoperative imaging 
with CT, MRI/MRCP and Endoscopic Ultrasound (EUS) can 
provide valuable information on both the size of the tumor 
and its relationship with the main pancreatic duct and use 
of intraoperative ultrasound at time of surgery can provide 
valuable real time information on orientation with MPD 
in borderline cases [3, 6]. However, once enucleation is 
started, there is no reliable way to diagnose injury to MPD or 
major side branch other than visual confirmation of leaking 
pancreatic fluid from disrupted duct. This is often difficult, 
especially in lesions deep in the pancreatic head due to 
bleeding and cautery eschar (Figure 3). A missed injury to 
MPD can be catastrophic and lead to significant morbidity 
post-operatively possibly requiring additional procedures. 
We believe that in such situations, our described technique 
of EAE can help identify any significant pancreatic leak at 
time of enucleation providing valuable information that 
can help guide further treatment. If a significant leak is 
appreciated, then one can proceed with standard resection 
(PD for head lesions or DP for lesions of the body and tail) 
and potentially save the patient from morbidity related 
to clinically significant POPF. If a leak is not seen, then 
surgical site can be drained externally, and procedure 
terminated with close post-operative follow up of drain 
output. Pancreatic stent is deployed after ERCP to reduce 
risk of post ERCP pancreatitis and to treat small pancreatic 
leaks that may not have been seen on pancreatogram. This 
approach has been summarized in Figure 4, in the form of 
a treatment strategy algorithm.
The described patient had a highly symptomatic 
insulinoma in the head of the pancreas in close proximity 
to the MPD. Where everyone agreed that surgery was 
required, there was a difference in opinion regarding the 
choice of treatment. Given close proximity of the tumor 
to the MPD, it would have been reasonable to proceed 
with a pancreatoduodenectomy however we were 
hesitant in subjecting a 17 year-old girl with an indolent 
pNET to potential long and short-term complications 
of major pancreatic resection. Use of EAE allowed for 
a safe enucleation and potentially avoided the risk of 
development of significant POPF. However, the potential 
benefit of EAE must be weighed against the small but real 
risk of post ERCP pancreatitis. Also arranging ERCP at time 
of surgery can present logistical challenges that may need 
to be addressed well in advance.
CONCLUSION
The described technique of EAE can be a viable 
treatment option for some patients with pNETs in close 
proximity to the MPD. It can potentially increase the 
safety of the procedure by earlier assessment of integrity 
of the MPD, decreasing risk of development of significant 
POPF and avoiding the morbidity associated with major 
pancreatic resections (PD, CP or DP). Additional studies 
are required before efficacy of EAE in management of 
pNETs can be clearly established.
Figure 3. Intraoperative image after enucleation. Approximately 2 × 2 cm 
defect in head of pancreas after enucleation of pNET (yellow circle). 
PH=pancreatic head; PB=pancreatic body; D=duodenum, black 
hyphenated line showing outline of pancreas, white hyphenated line 
tracing duodenal C-loop. 
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Figure 4. Treatment algorithm for patients with pNET being considered for ERCP assisted enucleation. 
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